Clinical Trials on Primary Acquired Nasolacrimal Duct Obstruction in Australia

Total 85 results

Medical University of Vienna

Completed

Nasolacrimal Duct Obstruction

Eye Diseases | Lacrimal Duct Obstruction

Austria
HighTide Biopharma Pty Ltd

Completed

A Study of HTD1801 in Healthy Subjects

Primary Sclerosing Cholangitis

Australia
Boston Scientific Corporation

Completed

SpyGlass AMEA Registry

Biliary Stricture | Periampullary Tumor | Biliary Obstruction Due to Common Bile Duct Stone | Hemobilia

Hong Kong, Korea, Republic of, Thailand, Australia, Saudi Arabia, Japan, India, Pakistan, Singapore, South Africa
Dr. Falk Pharma GmbH

Completed

Norursodeoxycholic Acid in the Treatment of Primary Sclerosing Cholangitis (NUC-3)

Primary Sclerosing Cholangitis

Austria, Germany, Norway
Dr. Falk Pharma GmbH

Recruiting

norUrsodeoxycholic Acid vs Placebo in PSC

Primary Sclerosing Cholangitis

Austria, Germany
Kirby Institute
Bristol-Myers Squibb; GlaxoSmithKline; Merck Sharp & Dohme LLC; Roche Pharma AG; Boehringer... and other collaborators

Completed

Can Resistance Enhance Selection of Treatment? (CREST)

HIV Infection

Australia
Pliant Therapeutics, Inc.

Completed

Phase 2a Evaluation of Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Patients With Primary Sclerosing Cholangitis (PSC)

Primary Sclerosing Cholangitis

United States, Belgium, Australia, Canada, Netherlands, Germany, Austria, United Kingdom, France
Salzburger Landeskliniken

Unknown

Bipolar Transurethral Enucleation (BipolEP) vs Bipolar Transurethral Resection of the Prostate

Benign Prostatic Hyperplasia | Bladder Outlet Obstruction

Austria, Switzerland
Bayside Health
University of Melbourne

Completed

Prevalence and Treatment of Urinary Incontinence in Women With Cystic Fibrosis and Chronic Obstructive Pulmonary Disease

Cystic Fibrosis | Chronic Obstructive Pulmonary Disease (COPD)

Australia
NGM Biopharmaceuticals, Inc
NGM Biopharmaceuticals Australia Pty Ltd

Completed

Phase 2b Study of NGM282 Extended Treatment in Patients With Primary Biliary Cirrhosis

Primary Biliary Cirrhosis

United States, Australia, New Zealand
NGM Biopharmaceuticals, Inc
NGM Biopharmaceuticals Australia Pty Ltd

Completed

Phase 2 Study of NGM282 in Patients With Primary Biliary Cirrhosis

Primary Biliary Cirrhosis

United States, Australia
OncoC4, Inc.
Avance Clinical; OncoC4 AU Pty Ltd

Recruiting

Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors (PRESERVE-009)

Melanoma | Renal Cell Carcinoma | Cervical Cancer | Hepatocellular Carcinoma | Gastric Cancer | Colorectal Cancer | Esophageal Cancer | Fallopian Tube Cancer | Non Small Cell Lung Cancer | Bile Duct Cancer | Bladder Cancer | Endometrial Cancer | Head and Neck Squamous Cell Carcinoma | Anal Cancer | Primary Peritoneal... and other conditions

Australia
Escient Pharmaceuticals, Inc
Novotech (Australia) Pty Limited

Completed

Evaluate the Safety, Tolerability, and PK of EP547 in Healthy Subjects and Subjects With Cholestatic or Uremic Pruritus

Pruritus | Cholestasis | Kidney Failure

Australia, New Zealand
Boston Scientific Corporation

Terminated

Minimally Invasive Prostatic Vapor Ablation for the Treatment of BPH in Large Prostates (Rezūm XL) (Rezūm XL)

BPH | BPH With Urinary Obstruction | BPH With Urinary Obstruction With Other Lower Urinary Tract Symptoms

United States, Australia
Medical University of Vienna

Completed

Preventing Cholestasis Using SMOFLipid®

Cholestasis | Psychomotor Disorders, Developmental

Austria
Gilead Sciences

Terminated

Study of Cilofexor in Adults With Primary Sclerosing Cholangitis (PRIMIS)

Primary Sclerosing Cholangitis

United States, Belgium, Israel, Spain, United Kingdom, Australia, Germany, New Zealand, Denmark, France, Japan, Switzerland, Austria, Canada, Finland, Italy
Gilead Sciences

Completed

Study to Evaluate the Safety, Tolerability, and Efficacy of Cilofexor in Adults With Primary Sclerosing Cholangitis Without Cirrhosis

Primary Sclerosing Cholangitis

United States, Canada, United Kingdom, Austria
The Alfred
National Health and Medical Research Council, Australia

Completed

Impact of HIV and Its Treatment on Reverse Cholesterol Transport

HIV Infections

Australia
Arena Pharmaceuticals

Terminated

Safety, Tolerability, and Efficacy of Etrasimod (APD334) in Participants With Primary Biliary Cholangitis

Primary Biliary Cholangitis

United States, Australia, New Zealand
Starpharma Pty Ltd
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

SPL7013 Gel - Male Tolerance Study

Human Immunodeficiency Virus (HIV)

Australia
University of Melbourne
Melbourne Health; National Institute of Allergy and Infectious Diseases (NIAID) and other collaborators

Completed

Effect of High Dose Vitamin D Supplementation on HIV Latency (VIVA)

Human Immunodeficiency Virus

Australia
Medical University of Graz

Completed

Safety and Efficacy of Long-Term Treatment With Atorvastatin in Patients With Primary Biliary Cirrhosis

Hypercholesterolemia | Primary Biliary Cirrhosis

Austria
407 Doctors
Bristol-Myers Squibb; Merck Sharp & Dohme LLC

Unknown

Once Daily 3TC, Efavirenz and ddI for HIV Infection

HIV Infection | AIDS

Australia
Medical University of Vienna

Completed

Impact of Visceral Osteopathic Treatment on Meconium Evacuation in Preterm Infants

Meconium Ileus

Austria
Enanta Pharmaceuticals, Inc
Pharmaceutical Research Associates; Triangle Biostatistics

Completed

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Primary Biliary Cholangitis

Primary Biliary Cholangitis

United States, Spain, Canada, Australia, United Kingdom, Germany, Netherlands, Belgium, Austria, France
Intercept Pharmaceuticals

Completed

Phase 3 Study of Obeticholic Acid in Patients With Primary Biliary Cirrhosis (POISE)

Primary Biliary Cirrhosis

United States, Spain, United Kingdom, Austria, Netherlands, Australia, Italy, Germany, Poland, Sweden, France, Canada, Belgium
University of California, San Francisco
National Institute of Allergy and Infectious Diseases (NIAID); Monash University and other collaborators

Completed

Short-term Disulfiram Administration to Reverse Latent HIV Infection: a Dose Escalation Study

HIV | Human Immunodeficiency Virus

United States, Australia
CymaBay Therapeutics, Inc.

Completed

ENHANCE: Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Response to or an Intolerance to Ursodeoxycholic Acid (UDCA)

Primary Biliary Cholangitis

United States, Spain, United Kingdom, Israel, France, Korea, Republic of, Australia, Italy, Hungary, Germany, Romania, Belgium, Canada, Greece, New Zealand, Austria, Serbia, Russian Federation, Argentina, Mexico, Netherlands, Chile, Polan...
Andrew Carr
ViiV Healthcare Australia Pty. Ltd

Completed

The Tolerability of, and Adherence to, Dolutegravir With Co-formulated Tenofovir-emtricitabine for HIV Non-occupational Post-exposure Prophylaxis (dPEP)

Human Immunodeficiency Virus

Australia
Bayside Health

Terminated

Associations, Outcomes and Genomics of GB Virus C, Hepatitis C Virus and Human Immunodeficiency Virus Infection

HIV Infections | Hepatitis C

Australia
CymaBay Therapeutics, Inc.

Recruiting

Seladelpar in Subjects With Primary Biliary Cholangitis (PBC)

Primary Biliary Cirrhosis

United States, Korea, Republic of, Belgium, Spain, France, Switzerland, Romania, United Kingdom, Austria, Israel, Australia, Argentina, Canada, Chile, Germany, Greece, Hungary, Italy, Mexico, Netherlands, Poland, Czechia, New Zealand, Turke... and more
Kirby Institute
Merck Sharp & Dohme LLC

Completed

The Effect of Raltegravir on HIV Decay During Primary and Chronic Infection (PINT)

HIV Infection

Australia
Calliditas Therapeutics Suisse SA

Active, not recruiting

A Trial of Setanaxib in Patients With Primary Biliary Cholangitis (PBC) and Liver Stiffness (TRANSFORM)

Primary Biliary Cholangitis | Liver Stiffness

United States, Spain, France, Australia, Israel, Canada, Switzerland, Italy, New Zealand, Germany, Poland, Greece, United Kingdom, Belgium, Austria, Czechia, Hungary, Sweden
Intercept Pharmaceuticals

Active, not recruiting

Study of OCA in Combination With BZF Evaluating Efficacy, Safety, and Tolerability in Participants With PBC

Primary Biliary Cholangitis

Netherlands, United Kingdom, Korea, Republic of, Germany, Australia, Estonia, Belgium, France, Czechia, Croatia, Greece, Hungary, Israel, Lithuania, Norway, Poland, Spain
Intercept Pharmaceuticals

Completed

Study of INT-747 as Monotherapy in Participants With Primary Biliary Cirrhosis (PBC)

Liver Cirrhosis, Biliary

United States, France, Germany, Spain, United Kingdom, Canada, Austria
Gilead Sciences

Terminated

Study to Evaluate the Safety, Tolerability, and Efficacy of Cilofexor in Adults With Primary Biliary Cholangitis Without Cirrhosis (PBC-Phase 2)

Primary Biliary Cholangitis

United States, Canada, Austria, United Kingdom
Intercept Pharmaceuticals

Terminated

Study of Obeticholic Acid (OCA) Evaluating Pharmacokinetics and Safety in Participants With Primary Biliary Cholangitis (PBC) and Hepatic Impairment

Liver Cirrhosis, Biliary

United States, Argentina, Spain, Belgium, Germany, Canada, Australia, Estonia, Brazil, Hungary, Italy, Lithuania
Bruce Brew
ViiV Healthcare

Completed

A Study of the Neurological Effects of Adding Maraviroc to HAART Regimen in Patients With HIV (HANDmac) (HANDmac)

Human Immunodeficiency Virus (HIV) | HIV Associated Neurocognitive Disorders (HAND)

Australia
Medical University of Vienna

Completed

Retinal Oxygen Reactivity in Patients Infected With Human Immunodeficiency Virus (HIV)

HIV Infections | Ocular Physiology | Retina

Austria
St Vincent's Hospital, Sydney
Merck Sharp & Dohme LLC

Terminated

A Study of the Neurological Effects of Adding Raltegravir to HAART Regimen in Patients With HIV (HANDral)

Human Immunodeficiency Virus (HIV) | HIV Associated Neurocognitive Disorders (HAND)

Australia
Intercept Pharmaceuticals

Terminated

Phase 4 Study of Obeticholic Acid Evaluating Clinical Outcomes in Patients With Primary Biliary Cholangitis (COBALT)

Liver Cirrhosis, Biliary

United States, Spain, Korea, Republic of, Australia, Finland, Israel, Lithuania, United Kingdom, Belgium, Netherlands, Estonia, Brazil, Italy, Serbia, Sweden, Argentina, Austria, Canada, Chile, Denmark, France, Germany, Hong Kong, Hun... and more
Medical University of Vienna

Unknown

Comparison of Stenting Versus Best Medical Therapy for Treatment of Ostial Renal Artery Stenosis: a Trial in Patients With Advanced Atherosclerosis

Renal Artery Stenosis

Austria
GlaxoSmithKline

Completed

Dose Response Study of GSK2330672 for the Treatment of Pruritus in Participants With Primary Biliary Cholangitis

Cholestasis

United States, Australia, France, Spain, Germany, Canada, Japan, United Kingdom, Italy, Poland
CymaBay Therapeutics, Inc.

Completed

RESPONSE: Response to Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Control to or an Intolerance to Ursodeoxycholic Acid (UDCA)

Primary Biliary Cholangitis

United States, Spain, France, Korea, Republic of, Denmark, Australia, Italy, United Kingdom, Belgium, Canada, Russian Federation, Romania, Germany, Hungary, Mexico, Turkey, Argentina, Austria, Chile, Czechia, Greece, Israel, New Zealand and more
Medical University of Graz

Recruiting

Urethral Stricture Database

Urethral Stricture

Austria
Elevation Oncology

Active, not recruiting

Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors

Sarcoma | Kidney Cancer | Breast Cancer | Head and Neck Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Lung Cancer | Prostate Cancer | Cholangiocarcinoma | Bile Duct Cancer | Bladder Cancer | Metastatic Solid Tumor | Gallbladder Cancer | Uterine Cancer | Locally Advanced Solid Tumor

United States, Korea, Republic of, Australia, Canada
Glaxo Wellcome

Completed

The Antiviral Efficacy of Concurrent Zidovudine and 2',3'-Dideoxyinosine or 2',3'-Dideoxycytidine in Patients With Human Immunodeficiency Virus Disease

HIV Infections

United States, Puerto Rico, Australia
Janssen-Cilag International NV

Completed

Treatment Simplification by Darunavir/Ritonavir 800/100 mg Once a Day Versus a Triple Combination Therapy With Darunavir/Ritonavir (MONET)

HIV Infections | Human Immunodeficiency Virus | Acquired Immunodeficiency Syndrome Virus | AIDS Virus

United Kingdom, Belgium, Germany, Spain, Portugal, Israel, Denmark, Russian Federation, Austria, Hungary, Switzerland
Medical University of Vienna

Recruiting

Vienna HIV Infection Via Sex Study (HIVEX)

HIV Infections | Sexually Transmitted Diseases | Chlamydia | Gonorrhea | Syphilis | HIV Pre-Exposure Prophylaxis

Austria
Pfizer

Active, not recruiting

Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors.

Renal Cell Carcinoma | Gastric Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Squamous Cell Carcinoma of the Head and Neck | Bile Duct Cancer | Endometrial Cancer | Urothelial Cancer | Lung Squamous Cell Carcinoma | Melanoma Cancer

United States, Taiwan, Korea, Republic of, Australia, Slovakia

Clinical Trials on Primary Acquired Nasolacrimal Duct Obstruction in Australia

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Burkina Faso

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations